Ann: Presentation-Surgical Resection Outcomes and Capital Raising, page-18

Interestingly unexpected interactions between different oncologic agents certainly occasionally do occur e.g. one modality counteracting another. You can't read anything into the figures presented, however. I don't see the Oncosil implant having much use in aiding the cure of pancreatic cancer (early detection and resection is the only way to do that at present), but its value might be in palliative management if the side effect profile is acceptable and efficacy is proven - chemotherapy is poorly tolerated and results in significant time in hospital and day units, SBRT is excellent and well-tolerated but requires stereotactic capability, EUS placement of fiducial markers and a few visits to the radiotherapy unit, whereas an implant requires just EUS placement.